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Abstract In the prospect of improved disease manage-
ment and future clinical trials in Frontotemporal Dementia,
it is desirable to share common diagnostic procedures. To
this aim, the Italian FTD Network, under the aegis of the
Italian Neurological Society for Dementia, has been
established. Currently, 85 Italian Centers involved in
dementia care are part of the network. Each Center com-
pleted a questionnaire on the local clinical procedures,
focused on (1) clinical assessment, (2) use of neuroimaging
and genetics; (3) support for patients and caregivers; (4) an
opinion about the prevalence of FTD. The analyses of the
results documented a comprehensive clinical and
instrumental approach to FTD patients and their caregivers
in Italy, with about 1,000 newly diagnosed cases per year
and 2,500 patients currently followed by the participating
Centers. In analogy to other European FTD consortia,
future aims will be devoted to collect data on epidemiology
of FTD and its subtypes and to provide harmonization of
procedures among Centers.
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Frontotemporal Dementia (FTD) is considered one of the
most important neurodegenerative conditions after Alz-
heimer Disease (AD), affecting the presenium as well as
the aged population. Atrophy predominantly involves the
frontal and temporal lobes, in which, at autopsy, the dis-
tinctive hallmarks are mainly constituted by microtubule
associated protein tau (MAPT) depositions, TAR DNA-
binding protein 43 (TDP-43) inclusions, or to a lesser
extent, fused in sarcoma inclusions (FUS) [1]. Social
misconduct, language and executive deficits, or motor
impairment are the main features at disease onset, therefore
encompassing different clinical syndromes: the behavioral
variant FTD (bvFTD), the nonfluent/agrammatic (nf/av-
PPA) and semantic (svPPA) variants of primary progres-
sive aphasia [2–4]. Amyotrophic Lateral Sclerosis (ALS)
or atypical extrapyramidal syndromes are variably repre-
sented during the disease course. Furthermore, the recog-
nition of a common clinical, genetic and pathological
overlap of FTD with Corticobasal Degeneration Syndrome
(CBS), Progressive Supranuclear Palsy (PSP) and ALS
(ALS/FTD) suggested the inclusion of these relatively rare
conditions under the same nosological group. As the dis-
ease progresses, the different FTD variants tend to overlap,
further contributing to the complexity of the clinical pic-
tures. FTD is a sporadic disease, but a strong genetic
background, with almost 40 % of patients showing a
positive family history, prompted the identification of a
number of genes causative of the disease. Mutations in
MAPT, granulin (GRN), and more recently in the hexanu-
cleotide repeat expansion in C9orf72, are considered the
most frequent causes of genetic FTD [1].
Despite the great effort to find genes associated with the
disease, FTD is still poorly recognized, as demonstrated by
sparse and controversial epidemiological data on its prev-
alence, incidence or main demographic characteristics [2–
4]. Literature data provide several clinical classification
systems, promoting a wider recognition of the disease
although limited to experienced clinical settings. The wide
clinical, pathological and genetic variability, along with the
small number of patients, have, so far, prevented the
development of large clinical trials for a devastating con-
dition still orphan of any therapeutic approach.
In this scenario, it is desirable to share common diag-
nostic procedures to improve major disease recognition
along with its management, also in the prospect of future
clinical trials. To this aim, the Italian FTD network, under
the aegis of the Italian Neurological Society for Dementia
(SINDEM), promoted a survey among its participants to
collect data about general clinical ground, focused on (1)
the clinical assessment, (2) the use of neuroimaging and
genetics; (3) the support for patients and caregivers; (4) and
the personal opinion about the prevalence of FTD.
Subjects and methods
This multicenter, national survey has been developed under
the auspices of the Italian Neurological Society for
Dementia (SINDEM). A semi-structured questionnaire was
e-mailed to dementia Centers belonging to SINDEM. The
group was made by both primary and tertiary Referral
Centers, covering the Country from the North to South.
Each Center was required to fill in a 15-point questionnaire
to map existing services and resources in Italy. Participants
were asked to specify the site they worked in and their
specialization (see supplementary data, i.e. the English
translation of the questionnaire).
The questionnaire included either closed (yes/no) or
multiple choice responses. Clinicians were asked to mark
on a visual rating scale their opinion about the broad
prevalence of FTD as compared to AD. In addition, the
number of new patients diagnosed and followed per year
was requested.
The questionnaire focused on the diagnostic procedures
in clinical practice, as follows: (1) clinical assessment
adopted to diagnose FTD, (2) the use of neuroimaging
investigations, (3) the availability of biomarkers and
genetic analyses, and (4) the resources for supporting
patients and caregivers.
In particular, the clinicians were asked to identify clin-
ical features suggesting FTD, encompassing the onset in
the presenium, behavioral disorders, language disorders
and positive family history for dementia. They indicated
their opinion about the co-occurrence of ALS and a posi-
tive psychiatric history.
A multiple choice query investigated the comprehensive
workup adopted for diagnosis, including specific neuro-
psychological battery test examination, structural neuro-
imaging (CT or MRI) or functional neuroimaging (brain
FDG-PET), along with genetic and cerebrospinal fluid
(CSF) analysis. The in loco specific facilities were
recorded.
F. Tagliavini
Department of Diagnostics and Applied Technology,
Division of Neurology 5 - Neuropathology,
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan,
Italy
L. Tremolizzo
Neurology Section, DCMT, University of Milano Bicocca
Monza and NeuroMi-Milan Center for Neuroscience,
Milan, Italy
A. C. Bruni
Regional Neurogenetic Center, ASPCZ, Lamezia Terme, Italy
Neurol Sci
123
Furthermore, psychosocial services offered to patients
and caregivers, including genetic counseling and cognitive/
rehabilitative programs, were investigated. Modalities to
hospital admission for diagnosis were defined.
Data analysis
Statistical analysis was performed using Statistical Package
for the Social Sciences, SPSS vers. 19. Results were cal-
culated according to the percentage of responses.
Results
Ninety-four out of 107 referral Centers filled in the ques-
tionnaire (response rate: 87.8 %), and 85 agreed to par-
ticipate in the FTD Group-SINDEM network.
The geographical distribution of the participating Cen-
ters is reported in Fig. 1; 60 % were from the North of
Italy, 22 from the Center and 18 % from the South. Uni-
versity Centers were 36.4 % of the total.
The majority of clinicians resulted specialized in Neu-
rology (95 %), whilst the others in Geriatrics (4 %) or had
a genetics and neuropsychological professional background
(1 %).
Data of the visual rating scale indicated that FTD is
considered less frequent compared to AD in aged popula-
tion, and as prevalent as AD in early-onset disease.
The key symptoms for suspecting FTD were language
deficits and behavioral disorders (98.9 and 95.7 % of cases,
respectively), followed by early disease onset (76.3 %) and
positive family history for dementia (62.7 %) (see Fig. 2,
Panel A).
In almost all the Centers, the diagnostic workup was
accomplished by full neuropsychological evaluation
(95.7 %) and structural neuroimaging (91.5 %). Functional
neuroimaging (brain FDG-PET) is provided in almost
75 % of case, whilst genetic (53.2 %) and cerebrospinal
fluid (50.0 %) analyses were available in half of the cases
(see Fig. 2, Panel B).
History of a psychiatric disorder was taken into account
in 74 % of the sample, and the presence of motor neuron
disease was frequently assessed clinically (65 %). Only
17 % of the Centers adopted, if necessary, neurophysio-
logical examinations to examine motor neuron involve-
ment suggestive of ALS (ALS/FTD).
Facilities for biomarkers assessment (i.e. cerebrospinal
fluid analyses) were available in 56 % of the Centers.
Genetic analyses were carried out locally in only 36 % of
the Centers, with genetic counseling in the half of the cases
(52 %) (see Fig. 3).
Concerning psychological support, only 52 % of the
involved Centers may provide patient/caregiver support,
and 42 % have programs of cognitive stimulation/rehabi-
litation (see Fig. 3).
A total number of about 1,000 newly diagnosed patients
per year were collected summing up the number indicated
by each Center, 67 % of them accessing to an outpatient
facility (see Fig. 3). The number of patients with FTD
currently followed in Italy by the participating Centers was
2,500. Considering that the Italian population is about
60,000,000 of inhabitants, the broad prevalence of the
disease was four cases out of 100,000.
Considering the population over 50 years of age (almost
24,000,000), FTD prevalence was estimated at 10 cases out
of 100,000.
Discussion
In this study, we present the results from the first survey
involving a large number of Italian dementia Centers
concerning the general recognition, management and
opinion on FTD.
Among all the Centers invited to complete the e-mail
questionnaire, eighty-five Italian Centers took part in the
interview and agreed to be part of the Italian FTD Network.
A preliminary analysis of the results showed that pre-
senile onset and a positive family history for dementia and/
or psychiatric disorder are additional elements considered
in the diagnostic workup. Co-occurrence of ALS is also
Fig. 1 Geographical distribution of the Italian Centers participating
in the FTD-Group SINDEM
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widely considered. The vast majority of dementia centers
accomplish diagnosis using specific neuropsychological
evaluation and a structural neuroimaging examination. In
most of the cases, functional neuroimaging is also per-
formed. In half of the cases, genetic and cerebrospinal fluid
analyses are available, along with genetic counseling.
Regarding the determination of CSF biomarkers, the ana-
lysis was performed in patients with memory disturbances
to exclude an amyloid-based pathology, whereas in the
presence of typical symptoms (behavioral and/or language
impairment) and structural neuroimaging showing focal
frontal left atrophy, criteria for diagnosis [3] were met
without any further additional procedure.
The genetic analysis is available in 36 % of the Centers,
mainly due to technical required expertise and high costs
required to perform the analysis. Nevertheless, the low
percentage reported is in part due to ethical concerns of
local committees in disclosing a monogenic disease, with
clear implications on family members.
About half of the Centers provide patient/caregiver
support and cognitive rehabilitation. Early-onset FTD is
considered to be as prevalent as early-onset AD.
The general scenario from these data document a com-
prehensive and satisfactory general clinical and instru-
mental approach to FTD patients and their caregivers, with
about 1,000 newly diagnosed cases per year.
Future goals will be directed at implementing the net-
work between tertiary referral Centers and participating
primary care Centers, with the aim to improve FTD diag-
nosis and management.
In analogy to other European FTD consortia, future aims
of the Italian FTD Network will be devoted to collect
further data on the epidemiology of FTD and its subtypes,
to develop guidelines for early diagnosis and follow-up,
Fig. 2 Survey of diagnostic
procedures in Italy Panel
a Symptoms suggestive for
Frontotemporal Dementia.
Panel b Diagnostic workup




Fig. 3 Clinical, instrumental and psychosocial services offered to patients and caregivers in the involved dementia Centers
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and disseminate procedures for genetic analyses and
counseling. Providing harmonization of procedures and
allowing selection for evidence-based therapeutic strate-
gies, will play a key role for a better management of the
disease.
Acknowledgments This study was supported by grants from the
Cassa di Risparmio di Pistoia e Pescia (CRPT 2013/0347) to B.N.,
from Italian Ministry of Health RF-2010-2319722 to S.S. and F.T.,
from Ricerca Corrente, Italian Ministry of Health to R.G., E.S. and
F.T., from Ricerca Finalizzata Italian Ministry of Health RF-2009-
1473856 to V.S. and from PRIN 2011 to S.F.C., from Fondazione
Cassa Risparmio di Parma Res.contracts 2008-2013 Italian Minister
of Health RF 2010-2311041 to P.C.
Conflict of interest The authors declare that there is no conflict of
interests regarding the publication of this paper.
FTD Group-SINDEM co-authors (in alphabetic order)
Agosta F.14, Alberoni M.15, Appollonio I.12, Arighi A.2,
Avanzi S.16, Baglio F.15, Benussi L.7, Bianchetti A.17,
Binetti G.7, Bonanni L.18, Bottacchi E.19, Bruno G.20,
Canevelli M.20, Canu E.21, Cerami C.22, Chiari A.23, Conti
MZ.24, Costa A.25, Costa M.26, Cotelli M.27, Cotelli MS.28,
Cupidi C.13, Daniele A.29, D’Anna S. 30, De Caro MF.31,
De Togni L.32, Dell’Osa MT.33, Di Stefano F.34, Ferrarese
C.12; Ferrari C. 3, Filastro F.35, Floris G.34, Franceschi
M.36, Gennuso M.37, Ghidoni E. 38, Giordana MT.39,
Gragnaniello D.40, Grimaldi L.41, Lanari A.42, Le Pira F.43,
Lombardi G.3, Lorusso S.44, Ludovico L.45, Luzzi S.46,
Magnani G.14, Manfredi LG.47, Marano P.48, Marcone
A.22, Marrosu MG.49, Martorana A.50, Mascia MG.51,
Masullo C.52, Mauri M.53, Mazzone A.54, Mela A.21, Merlo
P.55, Micheli A.56, Milia A.51, Mina C.57, Montella P.58,
Mura G.59, Murru MR.49; Nemni R.15, Paci C.60, Pantieri
R.61, Panza F. 62, Parnetti L.63, Perini M.64, Pettenati C.65,
Piccininni M.66, Piccoli T.67, Pilia G.51, Pinessi L.9, Piras
MR.49, Realmuto S.68, Ricca I.69, Rizzetti MC.70, Rozzini
L.71, Rubino E.9, Sambati L.72, Seripa D.62, Siano P.73,
Sinforiani E.74, Sorrentino G.75, Specchio LM.76, Stracciari
A.77, Susani E.12,Talarico G.20, Tartaglione B.31, Tessitore
A.58, Thomas A.18, Tiezzi A.78, Tiraboschi P.11, Tognoni
G.79, Tondelli M.23, Trebbastoni A.80, Turla M.28, Ursini
F.81, Valluzzi F.82, Vista M. 83, Zannino G.84, Zanusso
G.85.
2Department of Pathophysiology and Transplantation,
‘‘Dino Ferrari’’ Center, University of Milan, Fondazione
Ca` Granda, IRCCS Ospedale Policlinico, Milan;
3Department of Neuroscience, Psychology, Drug Research
and Child Health, University of Florence, Florence;
7IRCCS S. Giovanni di Dio Fatebenefratelli, Brescia;
9Neurology Unit, Department of Neuroscience, University
of Turin, Turin; 11Department of Diagnostics and Applied
Technology, Division of Neurology 5–Neuropathology,
Fondazione IRCCS Istituto Neurologico Carlo Besta,
Milan; 12Neurology Section, DCMT, University of Milano
Bicocca, Monza and ‘‘NeuroMi-Milan Center for Neuro-
science; 13Regional Neurogenetic Center, ASP CZ Lame-
zia Terme; 14Neuroimaging Research Unit, Institute of
Experimental Neurology, Division of Neuroscience,
Department of Neurology San Raffaele Scientific Institute,
Vita-Salute San Raffaele University, Milan, Italy; 15IRCSS
S.M. Nascente, Milan; 16IRCCS Maugeri, Castel Goffredo,
Mantova; 17S. Anna Hospital, ICSA Gruppo San Donato,
Brescia; 18Department of Neuroscience and Imaging,
University of Chieti-Pescara, Chieti; 19Regional Hospital,
Aosta; 20Clinica della Memoria, Dip. di Neurologia e
Psichiatria, Univ. Sapienza Roma; 21San Francesco Hos-
pital, Nuoro; 22 Clinical Neurosciences Department, San
Raffaele Hospital (OSR), Milan; 23Civile Hospital S.Ag-
ostino Estense; Modena; 24Gusmini Foundation, Bergamo;
25Genetic Unit, IRCSS Mondino Pavia; 26Ramazzini Hos-
pital, Carpi, Modena; 27IRCCS Neuropsicology, Brescia;
28Vallecamonica Hospital, Brescia; 29Catholic University,
Institute of Neurology, Rome; 30Portogruaro Hospital,
Portogruaro-VE; 31Policlinico Hospital, Neurologia II,
Bari; 32ULSS 20, Verona; 33UVA, ASL Sassari; 34Centro
UVA, Neurologia, AOU Cagliari; 35Centro UVA Girifalco,
ASP Catanzaro; 36Neurology Department, Multimedica
Castellanza, Varese; 37UVA Maggiore Hospital, Crema;
38S. Maria Nuova Hospital, Reggio Emilia; 39Department
of Neuroscience, University of Turin, Turin; 40AO Ferrara,
Ferrara; 41San Raffaele Hospital, Cefalu’- PA; 42Poma
Hospital, Mantova; 43 University of Catania, Catania;
44Rimini Hospital, Rimini; 45AUSL Parma–Fidenza,
Parma; 46Department of Experimental and Clinical Medi-
cine, Marche Polytechnic University; 47Pio X Hospital,
Milan; 48Villa Gerani Hospital, Catania; 49Neurological
Clinic AOU Sassari, Sassari-Multiple Sclerosis Centre,
ASL 8-Cagliari/Department of Public Health, Clinical and
Molecular Medicine, University of Cagliari; 50Tor Vergata
University, Rome; 51S. Trinita` Hospital, Cagliari;
52Catholic Univeristy, S. Giovanni Hospital, Rome;
53Circolo Hospital, Varese; 54Geriatric UVA San Gerardo
Hospital, Monza; 55U.O. of Neurology -UVA, Humanitas
Gavazzeni, Bergamo; 56S. Francesco Clinic, Bergamo;
57UVA Sapienza University, Roma; 58II" University of
Naples, Naples; 59G.Paolo II Hospital, Olbia; 60San
Benedetto del Tronto Hospital, San Benedetto T.- AP;
61IRCCS Istituto delle scienze neurologiche di Bologna,
Ospedale Bellaria, Bologna; 62IRCSS ‘‘Casa sollievo della
sofferenza’’ S.G. Rotondo–FG; 63University of Perugia,
Perugia; 64AO Gallarate, Varese; 65AO G.Salvini, Passir-
ana-Rho-MI; 66ASL 10, Firenze; 67Dipartimento di Bio-
medicina Sperimentale e Neuroscienze Cliniche,
Universita` degli Studi di Palermo, Palermo; 68U.O. di
Neurol Sci
123
Neurologia e Neurofisiopatologia, Dipartimento di
Emergenza urgenza e neuroscienze, AUOP Paolo Giac-
cone, Palermo; 69Experimental Neurobiology Lab., C.
Mondino National Neurological Institute, Pavia; 70S. Isid-
oro Hospital -FERB Onlus, Trescore Balneario -BG;
71UVA Spedali Civili Hospital, Brescia; 72University of
Bologna, Bologna; 73AOU S.Giovanni e Ruggi, Salerno;
74Alzheimer’s Assessment Unit/Laboratory of Neuropsy-
chology, C. Mondino National Neurological Institute,
Pavia; 75Ist. Hermitage–Capodimonte, Naples; 76Riuniti
Hospital, Foggia; 77Neurology, S.Orsola-Malpighi Hospi-
tal, Bologna; 78AUSL 8, Arezzo; 79AO Pisa, Pisa; 80UVA
NPD 01 Sapienza University Rome; 81Campus Bio-Medico
University, Rome; 82ASL Monopoli–BA; 83UVA ASL 2
Lucca, Lucca; 84UVA Trebisacce Hospital, Cosenza;
85University of Verona, Verona.
References
1. Sieben A, Van Langenhove T, Engelborghs S, Martin JJ, Boon P,
Cras P, De Deyn PP, Santens P, Van Broeckhoven C, Cruts M
(2012) The genetics and neuropathology of frontotemporal lobar
degeneration. Acta Neuropathol 124:353–372
2. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S,
Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller
BL, Cummings J, Benson DF (1998) Frontotemporal lobar
degeneration: a consensus of clinical diagnostic criteria. Neurol-
ogy 51(6):1546–1554
3. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH,
Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU,
Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin
KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham
CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN,
Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam
M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F,
Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F,
Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL
(2011) Sensitivity of revised diagnostic criteria for the behavioural
variant of frontotemporal dementia. Brain 134:2456–2477
4. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez
M, Cappa SF, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF,
Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson
K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman
M (2011) Classification of primary progressive aphasia and its
variants. Neurology 76:1006–1014
Neurol Sci
123
